PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
Provided By GlobeNewswire
Last update: Oct 2, 2024
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)
88% (15/17) of patients had a complete metabolic response
IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024
